Printer Friendly

OXiGENE REPORTS ADDITIONAL DATA ON SENSAMIDE

 NEW YORK, Oct. 20 /PRNewswire/ -- OXiGENE Inc. (Nasdaq-NNM: OXGN) today announced that recently concluded animal studies have demonstrated that the company's lead compound, Neu-Sensamide(TM), reduces sedation, a side effect of radio and chemotherapy used in the treatment of cancer patients. Neu-Sensamide is a neutralized formulation of the company's radiosensitizer, Sensamide(TM), whose active ingredient is metoclopramide.
 These results were reported at the 11th International Symposium on ADP Ribosylation, DNA Repair and Signal Transduction, which was held recently in Strasbourg, France.
 Additionally, Dr. Ronald W. Pero, co-founder and chief scientist at OXiGENE, presented laboratory data confirming that combining the mode of action of Sensamide with radiation therapy chemically inactivates protein thiols such as those present in the DNA repair enzyme Adenosine Diphosphate Ribosyl transferase. This mode of action is thought to be responsible for the enhanced destruction of tumor cells relative to normal cells when Sensamide is administered adjunct to radiation therapy.
 Pero presented this data at the 13th meeting of the European Society for Therapeutic Radiation Oncologists recently held in Granada, Spain.
 Richard A. Brown, the company's chairman said, "We are very pleased that these animal studies demonstrated a reduced side effect and explain the reasons Sensamide has been shown to be safe to normal tissue."
 OXiGENE Inc. is engaged in the design and development of drugs based on proprietary technology that involves the inhibition, measurement and stimulation of the body's cellular DNA repair processes specifically related to the enhancement of radiation and chemotherapy and for the prevention of cancer and aging disorders.
 -0- 10/20/94
 /CONTACT: Richard Brown of OXiGENE, 212-421-0001/
 (OXGN)


CO: OXiGENE Inc. ST: New York IN: MTC SU: PDT

EQ-MO -- LA008 -- 6269 10/20/94 06:01 EDT
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 20, 1994
Words:284
Previous Article:MEGAHERTZ ANNOUNCES FIRST QUARTER 1995 SALES AND EARNINGS
Next Article:SCHULER HOMES INC. ANNOUNCES INCREASED QUARTERLY SALES AND NET INCOME FOR THE THIRD QUARTER 1994
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters